Orchid Chemicals & Pharmaceuticals has received formal approval from the US FDA for its abbreviated new drug application (ANDA) for formulation product Cefazolin for Injection USP - in 500 mg/vial and 1 gm / vial strengths.According to a release issued by the company to the BSE today, "this is the first ANDA approval for the company. The approval by USFDA for the ANDA will enable the company to launch the product in the US."
